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ABSTRACT
Background: Interleukin-10, IL-2 and IFN -γ are some of the crucial cytokines associated
with HIV infection and pathogenesis. While IL-2 and IFN-γ play critical roles in host
resistance to infection, IL-10 inhibits the synthesis IFN-γ, IL-2 at mRNA and protein
level; exacerbating damage to immune system.
Objective: To determine the levels of, changes in and correlation between CD4
count, viral load, IL-10, IL-2 and IFN-γ before HAART and at six months of HAART
among HIV positive patients in Kigali; with a view to understand cytokine networks
particularly in relation to HAART ; and to see whether they can be used as alternative
markers of the disease progression.
Design: Longitudinal study.
Setting: Kagugu, Kimironko, Biryogo, Gitega Health Centres and Centre Medico-Social 
Cornum; all located in Kigali.
Subjects: Thirty three (33) HAART initiation eligible HIV positive patients including 13
women and 20 men.
Results: A drop in viral load (though only a small number of patients achieved an
undetectable viraemia); a recovery of CD4+ cells, a decrease in IL-10 (though it remained
high for many patients especially those with unchanged viraemia); and an increase in
IL-2 and IFN-γ indicated a successful HAART . A negative correlation between CD4
count and viral load and between CD4 count and IL-10 (but r <-0.5) was observed. IL-10
correlated positively and strongly with viremia (r > 0.5 at both time points: p-values
<0.05). There was no significant correlation between CD4 count, IL-2 and IFN-γ.
Conclusion: Results demonstrated the down-regulatory effect of IL-10 on Th1 cytokines
and that a shift from Th1 to Th2 cytokine is associated with HIV disease progression.
A successful HAART results in CD4+ cells recovery, drop in viraemia and IL-10 with
up-regulation of Th1 cytokines. Also, findings show potential usefulness of IL-10 as
a marker of HIV disease progression.
INTRODUCTION
Global statistics from UNAIDS indicate that nearly
35 million people are currently infected with human
immunodeficiency virus (HIV), the causative agent
of acquired immunodeficiency syndrome (AIDS).
About two million people are infected each year, while
25 million people have died from HIV/AIDS since the
disease was first identified in the early 1980s (1).
 Human Immunodeficiency Virus is a lentivirus
belonging to the retroviridae family and is classified
into two types, HIV-1 and HIV-2. HIV-1 comprises of
groups M (major), N (non-M non-O), and O (outlier).
Due to a high level of genetic diversity, group M is
further sub-classified into subtypes (A to D; F to H;
J, and circulating recombinant forms). While HIV-2
remains essentially confined to West Africa, HIV-1
spreads around the world; with group M accounting
for the vast majority of HIV infections (2,3).
 Currently, viral load and CD4 count are the
only markers employed for HIV disease progression
assessment (4). Though less expensive compared to
viral load, CD4 cells count does not always correlate
with the viral load and disease progression and
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this brings need for affordable alternative markers
to assess the effects of treatment as well as disease
progression (5). Recent studies suggest a powerful
prognostic value for blood cytokines levels in different
diseases (6). Cytokines are polypeptides produced by
many different cell types mostly after their activation
to mediate inflammatory and immune reactions
(7).
 Structural studies have shown that cytokines
belong to one of the four groups: the hematopoietin 
family (participate to Haemopoiesis, for example, IL-
2), the interferon family (one of their functions is to 
interfere with viral replication within a host cell, for 
example,  IFN-γ), the chemokine family (Chemotactic 
molecules, for example, CCL14), or the tumour 
necrosis factor family (can induce cell death among 
other many functions, or example, TNF-α) (8).
 Tumour necrosis factor alpha (TNF-α), IFN-γ,
IL-1, IL-2, IL-6 and IL-10 are some of the cytokines
affected during HIV infection and analysis of these
cytokines may give an indication of the degree of
immune activation, the extent of the immune response
and disease progression (9). HIV infection has been
associated with reduced production of the Th1
cytokines, especially IL-2. Increases in Th2 cytokine
production particularly IL-4 and IL-10, restrict Th1
activity and are associated with HIV infection, as is a
skewing of the CD4+ T cell population toward a Th2
phenotype (1).
 Some studies on the secretion of cytokines in
the course of HIV infection, particularly following
HAART initiation have shown that CD4 count and
IL-2 correlate positively; but correlate negatively with
HIV load, IL-10 (10). While some studies suggested
a positive correlation between CD4 count, IL-2 and
IFN-γ; others have claimed a negative correlation
between this interferon and CD4+ cells count-IL-2
duo (11).
 IL-2 permits rapid and selective expansion of 
effector T cells (both CD4+ and CD8+) activated 
by antigen, among many other functions. IL-2 is a 
growth factor for NK cells and promotes production 
of NKderived cytokines like TNF-α, IFN-γ and GM-
CSF (12).
 IFN-γ activates transcription of a large number of
genes that play roles in anti-viral activity, apoptosis,
antigen processing, MHC protein expression, and
Th1 cells development (13).
 IL-10 is an important cytokine with 
antiinflammatory properties besides TGF-β and 
IL-35 (14,15). IL-10 suppresses all functions of 
monocytesmacrophages, and this impairs the role of 
these cells in both innate and adaptive immunity (16). 
IL-10 inhibits Th1 cell cytokines synthesis including 
IFN-γ, IL-2, IL-3, and GM-CSF at mRNA and protein 
level; inhibits the expression of costimulators and class 
II MHC molecules on macrophages and dendritic cells 
and because of these actions, IL-10 serves to inhibit T 
cell activation and terminate cell-mediated immune 
reactions (7).
 Although several studies have been done to
detail cytokine interactions in relation to HIV disease,
these interactions are yet to be fully understood (17).
In this study, the levels of CD4+ cells, IL-2, IL-10, and
IFN-γ were assessed and correlated with viral load
at the start of HAART and six months after HAART
initiation among HIV positive patients in Kigali/
Rwanda, where no such studies have been carried out.
This study will contribute to a better understanding
of the changes and interactions between various
cytokines in the course of HIV infection; in relation to
treatment. This study may also lead to identification
of additional and hopefully more affordable markers
for assessing HIV disease prognosis in relation to
treatment.
MATERIALS AND METHODS
Scientific and Ethical Consideration: A scientific review,
ethical clearance and a research permit were obtained
from the National Health Research Committee of the
Rwanda Biomedical Centre; the Rwanda National
Ethics committee and the Rwanda Ministry of
Education respectively.
Study Design: This was a six month (from August, 2013
to February, 2014) longitudinal study involving thirty
three (33) HAART initiation eligible HIV+ patients
(13 women and 20 men) recruited from Kagugu,
Kimironko, Biryogo, Gitega Health Centres and
Centre Medico-Social Cornum, all located in Kigali
City. All patients were taking Tenofovir Disoproxil
Fumarate Lamivudine and Efavirenz (tdf-3tc-efv)
tritherapy.
Sample size and sampling strategy: A correlation of -0.5
(r = - 0.5) between IL-10 and CD4+ T cells count was
anticipated. The minimum sample size to estimate the
same correlation with a Probability of Type I Error (α)
of 0.05, a Power (1 - β) of 0.8 was 20 patients (sample
size estimated using statstodo software available at
www.statstodo.com).
 Due to loss to follow up and death cases that are
normally recorded at the selected health facilities;
the sample size was raised to 40 HIV+ patients who
came for HAART initiation. Any patient who came
for HAART initiation was included in the sample size
until the desired number of 40 patients was reached.
At the end of the study, thirty three (33) patients were
still under follow up (four patients died and 
three were lost to follow up during the study).
Data collection: Variables considered during this study
included CD4 count, HIV plasma RNA, IL-10, IL-2 and
IFN-γ. Measurements were done on whole blood (CD4
count) and on its plasma (cytokines and the viral load).
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Blood was collected in 4 ml tubes containing EDTA at
two time points namely before HAART (August, 2013)
and six months following HAART initiation (February,
2014). Analyses were done at the Rwanda National
Refereral Laboratory according to the kits 
manufacturer’s instructions. CD4 count was done 
using flow cytometry while the viral load and 
cytokines were measured using the COBAS® 
AmpliPrep/COBAS® TaqMan® HIV-1 Test and 
ELISA techniques, respectively.
CD4 count: CD4 counts were performed using flow 
cytometry with Becton Dickinson FACSC alibur 
(Software: MultiSET V3.0.2).To 20μl of tritest (CD3/
CD45/CD4 monoclonal antibodies) reagent in 
TruCOUNT tube, 50μl EDTA whole blood was added.
Vortexing was done followed by a 15-minute 
incubation in the dark. This was followed by fixation 
and lysing for a further 15 minutes in dark. The sample 
analysis was then done.
Viral load determination: The viral load was measured
using The COBAS® AmpliPrep/COBAS® TaqMan®
HIV-1 test which is a nucleic acid amplification test for
the quantitation of Human Immunodeficiency Virus
Type 1 (HIV-1) RNA in human plasma done in three
major steps: Specimen preparation to release viral 
nucleic acid, reverse transcription of the target RNA 
to generate complementary DNA, simultaneous 
PCR amplification of target cDNA and detection of 
cleaved dual-labeled oligonucleotide probe specific to 
the target. In this procedure, specimen preparation is 
automated using the COBAS® AmpliPrep Instrument; 
amplification and detection are automated using the 
COBAS® TaqMan® Analyzer.
Cytokines quantification: IL-10, IL-2 and IFN-γ 
were measured using EL ISA techniques and 
this measurement involved addition of samples, 
standards and controls, conjugate, substrate-
chromogen and stop solutions to microtiter wells (test 
plate for IL-10, test plate for IL-2 and test plate for 
IFN-γ) coated with monoclonal antibodies specific 
to these cytokines; according to kits manufacturer’s 
instructions. Optical densities were measured at 450 
nm using a microtiter plate reader. Concentrations 
of the measured cytokines were determined using 
standard curves.
RESULTS
Specific objectives of this study were to determine 
the levels of, changes in and correlations between 
CD 4 count, viral load, IL-10, IL-2 and IFN-γ before 
HAART and at six months of HAART among HIV 
positive patients in Kigali/Rwanda. Thirty three (33) 
HIV positive patients participated to this study. These 
comprised of 20 (60.6%) men and 13 (39.4%) women 
with a mean age of 33 years. Results for cytokines are 
in pg/ml, CD 4 count in Cells/μl and the viral load in 
RNA copies/ml of blood. Significance of changes in 
the levels of measured variables was assessed using 
Wilcoxon signed rank test.
 At the time of HAART initiation, 32 (97%) of the
33 study participants had CD4 count <350 cells/μl of
blood. One patient (3%) had a CD4 count >350 cells/μl
of blood. When categorized based on whether the 
patient had a CD4 count below 200 cells/μl of blood 
(indicating a very low CD4 count) or more than 200 
cells/μl; 12 (36.3%) patients had less that 200 cells/
μl while 21 (63.7%) patients were having CD4 count 
of 200 cells/μl and above. Seven men (21.2%) and 5 
(15.2%) women had a CD4 count of less than 200 cells/
μl whereas 13 (39.3%) men and 8 (24.2%) women had 
a CD4 count of 200 cells/μl of blood and above. The 
mean CD4 count was 213 cells/μl of blood.
 After six months of HAART, 5 (15.1%) of the 33
patients had a CD4 count below 200 cells/μl namely
1 (3%) woman and four (12.2%) men. Twelve (36.3%)
women and 16 (48.4%) men had a CD4 count of 200 
cells/μl of blood and above. The mean CD4 count 
increased from 213 cells/μl of blood at HAART 
initiation to 369 cells/μl of blood after six months 
of treatment.
Table 1
Levels of CD4+ at HAART initiation and after six months of HAART. Results are presented based on sex and CD4 
counts are categorised into CD4 equal or above 200 cells/μl of blood and CD4 below 200 cells/μl of blood. Wilcoxon 













CD4 count of <200 
cells/μl of blood
12(36.4) 7(21.2) 5(15.1) 5(15.2) 4(12.2) 1(3)
Yes
CD4 count of 200 
cells/μl and above
21(63.6) 13(39.3) 8(24.2) 28(84.8) 16(48.5 12(36.3)
Before HAAT At six months of HAAT
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At HAART initiation, all study participants had high 
viremia. The median viral load was 23400 HIV RNA
copies/ml of plasma with a mean log of 4.5. Men had 
a median viral load of 22950 RNA copies/ml and a
mean log of 4.5 compared to 39500 RNA copies/ml
and a mean log of 4.7 for women. After six months
of HAART, the median viral load dropped to 661
RNA copies/ml with a mean log of 2.67. Viral load
median in men dropped to 612 RNA copies/ml and
to a mean log of 2.71 whereas the median reached
767 RNA copies/ml with a mean log of 2.61 among
women. When looked at individually, results show
that six (18.1%) patients achieved undetectable
viral load and five (15.1%) did not achieve any log
decrease in their viral load despite HAART for six
months.
Table 2
Viral load before HAART initiation and how it changed following HAART based on sex. Wilcoxon signed rank test 
showed a statistically significant change in viral load following HAART
Overall Men Women Overall Men Women Significant change 
following HAART
Median Viral load 23400 22950 39500 661 612 767 Yes
Mean Log viral load 4.59 4.5 4.7 2.67 2.7 2.7
Results are expressed in number of HIV RNA copies/ml of blood
As for cytokines levels before HAART and after six 
months of treatment; results show that the mean for IL-
10 was 120.2 pg/ml and this dropped to 48.06pg/ml 
at six months of HAART. As for the two Th1 cytokines 
namely IL-2 and IFN-γ; their means increased. Mean 
for IL-2 was 1.29 pg/ml at HAART initiation while 
the mean for IFN-γ was 0.84 pg/ml.
After six months of treatment, the two means raised 
10.8 and 5.24 pg/ml respectively. When change in 
the levels of these three cytokines was assessed using 
Wilcoxon signed rank test, a statistically significant 
decrease in IL-10 as well as an increase in IL-2 and 
IFN-γ were seen.
Before HAART At six months of HAART
Table 3
Levels of cytokines before HAART and at six months of treatment. The table shows overall means of the three 
cytokines measured in this study as well as means based on sex of participants. There was a statistically significant 
change in levels of measured cytokines
Significant change 
following HAART
Overall  Men Women Overall  Men Women
Mean IL-10 120.2 102.2 138.3 48.06 44.2 52.01 Yes
Mean IL-2 1.29 0.88 1.93 10.08 8.7 12.16 Yes
Mean IFN-γ 0.84 0.92 0.73 5.24 5.27 5.19 Yes
Results are expressed in pg/ml
Before HAART At six months of HAART
Variables were finally correlated between themselves. 
A negative correlation (r = -0.42; and r = -0.46 at p 
values <0.05) was observed between CD4 count and 
HIV plasma RNA; before HAART and at six months 
of the treatment. While a negative correlation was 
found between CD4 count and IL-10 (r < -0.5 at p 
values <0.05), a positive correlation was seen between 
CD4 count and IL-2 as well IFN-γ (however, these 
correlations were all weak, hence non-significant 
(r <-0.5 with most of all p values > 0.05). As for the 
correlations between HIV plasma RNA or the viral 
load and these cytokines; there was a strong positive 
correlation with IL-10 (r > 0.5; all p values <0.05) 
compared to the correlation viral load-CD4 count 
(r < -0.5). We did not find a significant correlation 
between the viral load and the two The cytokines 
(IL-2 and IFN-γ).
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Table 4
Correlation between variables measured in this study
CD4 count Viral load CD4 count Viral load
IL-10 -0.4 0.7 -0.2 0.7
IL-2 NS NS NS NS
IFN-γ 0.4 NS NS NS
CD4 count -0.42 -0.46
NS: Non significant correlation
DISCUSSION
While efforts have been made in providing AR V drugs
to infected people particularly in Africa; monitoring
of HIV positive patients to assess the response to AR V
as well as infection progression remains a challenge
especially due to scarcity of adequate facilities for the
biological follow up. CD4 count facilities have been
scaled up but the viral load measurement (which is
the current most reliable test to assess the progression
of the infection and response to treatment) is still
limited to a small number of health facilities and
this is particularly critical in Africa. Furthermore,
cytokines networks in the course of HIV infection is
yet to be fully understood. This study was done to
examine the relationship between cytokines, viral
load and CD4 count levels with a view to understand
cytokines networks during HIV infection as well
whether they can be used as alternative markers of
the disease progression, easily implementable and
affordable.
 In the present study; 33 HIV positive patients
were recruited and CD4 count, viral load, IL-10, IL-2,
and IFN-γ were measured; changes were rated and
correlations assessed both before HAART and at six
m o n t h s  a f t e r  i n i t i a t i o n  o f  t re a t m e n t .
Findings from this study have shown high levels of
HIV plasma RNA and high concentration of IL-10
before HAART. This has also been described by 
Agarwale et al (18). Furthermore, results from his 
study demonstrated that low CD4 count was also 
accompanied by low levels of Th1 cytokines (IL-2, 
IFN-gamma) and high levels of IL-10 (a Th2 cytokine) 
as it is the case from the present study at HAART 
initiation.
 In another study to assess IL-2 and IL-10 serum
levels in HIV-1-infected patients with or without
active anti-retroviral therapy, results similar to those
of the present study were found. Higher levels of
IL-10 have been detected in patients with low CD4
count, particularly those with CD4 count <200 cells/
μl of serum and higher levels of IL-10 paralleled with
high viral load (19).
 Another study by Ostrowski et al (20) suggested
that HIV-1 may directly subvert specific immune
responses by IL-10 induction. In this study, it was
found that Circulating frequencies of CD4+ T cells
constitutively producing IL-10 were significantly
higher in individuals with infection progression
or active HIV replication. HIV Gag antigen was
observed to induce IL-10 production from CD4+
T cells but the IL-10 level was dramatically down
regulated after HAART and these results are similar to
those found in the present study where a statistically
significant drop in IL-10 has been seen following
HAART. A significant drop in the viral load as well
as a statistically significant increase in secretion of
IFN-γ following HAART found in this study, have
also been documented by Sadeghi et al (21).
 Paris et al (22) also found that a drop in the viral load
was accompanied by a recovery of CD4 positive
cells following HAART with a negative correlation
between these two current HIV disease progression
markers. A positive correlation that was found
between IL-10 and viral load and CD4+ cells recovery
that went on with a significant increase in IL-2 and
IFN-γ (two Th1 cytokines) following HAART on the
other hand, had been mentioned by Osakwe (23).
Findings from this study have demonstrated the
suppressive property of IL-10 on the synthesis of Th1
cytokines (IL-2 and IFN-γ) which was associated with
high viraemia and a drop in CD4 count.
In conclusion, cytokines have a complex effect on 
the replication of HIV and conversely in infected 
individuals; HIV directly affects cytokine production. 
Different studies postulate that the progression of 
disease in HIV infected individuals may be controlled 
by the balance between the levels of type 1 (Th1) 
and type 2 cytokines (Th2). In this study, the down-
regulatory effect of IL-10 on Th1 cytokines as well 
as a shift from Th1 to Th2 cytokines in the course of
HIV disease progression have been demonstrated by
a number of elements including: A strong positive
correlation between viral load and IL-10; low CD4
Before HAART At six months of HAART
Correlation between measured variables
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count and low levels of the two Th1 cytokines which
were associated with high levels of IL-10 and viremia;
decrease in IL-10 and the viral load and a recovery
of CD4 positive cells, increase in IL-2 and IFN-γ
following HAART. This makes IL-10 a potential
alternative marker of HIV disease progression.
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